Harrow Completes Acquisition of TYRVAYA Nasal Spray for Dry Eye

Key Facts

1Harrow has completed its acquisition of TYRVAYA, the first and only FDA-approved nasal spray for the treatment of dry eye disease.

Harrow has completed its acquisition of TYRVAYA, the first and only FDA-approved nasal spray for the treatment of dry eye disease. GlobeNewswire reported that the company finalized the deal on October 5, 2026, expanding its ocular surface franchise with a unique, drop-free treatment option.

Harrow paid $30 million in cash at closing, with potential contingent milestone payments of up to $70 million tied to net sales, bringing the total consideration to a possible $100 million. Approximately 40 experienced personnel are expected to join Harrow's commercial team, with integration beginning in the fourth quarter of 2026 to support growth targets for 2027 and beyond.